USPTO serial 97716665
ORBITS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- SINGH, DEEP K
- Law office
- TMEG LAW OFFICE 101
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ORBITS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Clifford D. Hyra
Clifford D. Hyra FRESH IP PLC11710 PLAZA AMERICA DRIVE SUITE 2000RESTON, VA 20190UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable Software as a Medical Device (SaMD) for use in studying and analyzing cancer models and for use as medical image processors; Downloadable medical software for use in drug screening, drug discovery, image processing, image analysis and image storage and for use in studying and analyzing cancer models; Downloadable medical imaging software for recording, monitoring, studying and analyzing cancer models; Downloadable medical and scientific analysis software for use in drug screening, drug discovery, image processing, image analysis and image storage and for use in studying and analyzing cancer models; Downloadable software for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Downloadable cloud computing software for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Downloadable computer software platforms for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Downloadable software for analyzing microscopic images; Downloadable cloud computing software for analyzing microscopic images; Downloadable computer software platforms for analysing microscopic images; All the aforesaid in particular in the field of cancer research, cancer screening, cancer treatment and cancer diagnosis | ACTIVE | — |
| 042 | Providing online, non-downloadable software for use as a medical device for image processing and for studying and analyzing cancer models; Platform as a Service (PAAS) featuring computer software platforms for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Cloud computing featuring software for use in medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Providing temporary use of on-line non-downloadable cloud computing software for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Providing on-line non-downloadable software for medical imaging, image analysis, image storage, image transfer, drug screening, testing of pharmaceuticals and drug development; Software as a service (SAAS) services featuring software for medical imaging, image analysis, image storage and image transfer; Software as a service (SAAS) services featuring software for drug screening, testing of pharmaceuticals and drug development; Platform as a Service (PAAS) featuring computer software platforms for analyzing microscopic images; Cloud computing featuring software for use in analysing microscopic images; Providing temporary use of on-line on-downloadable cloud computing software for analysing microscopic images; Providing on-line non-downloadable software for analyzing microscopic images; Software as a service (SAAS) services featuring software for analyzing microscopic images; medical research laboratory services; Medical and scientific research in the field of medical imaging, image analysis, drug screening, testing of pharmaceuticals and drug development; Drug screening for scientific research purposes; Testing of pharmaceuticals; Drug discovery services; Pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; All the aforesaid also using artificial intelligence; All the aforesaid in particular in the field of cancer research, cancer screening, cancer treatment and cancer diagnosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 2, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 2, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jul 1, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 2, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 2, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 2, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 2, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 16, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 16, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 11, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 17, 2022 | NWAP | NEW APPLICATION ENTERED | — |